Cathie Wood’s ARK ETFs have once again made notable moves in the stock market on Monday, December 16th, 2024, with significant trades that may interest investors. The daily trade report reveals a continued focus on the genomic health sector, with ARK’s largest dollar-value trade being the purchase of 96243 shares of Intellia Therapeutics Inc (NASDAQ:), amounting to $1,241,534. This move is consistent with ARK’s bullish stance on the gene-editing company, as they also acquired shares in the previous trading sessions.
Additionally, ARK has increased its holdings in Pacific Biosciences (NASDAQ:) of California Inc (NASDAQ:PACB) by buying 274940 shares, with a total dollar value of $538,882. This investment aligns with ARK’s trend of supporting companies involved in genomics and biotechnology innovation.
In terms of sales, ARK has reduced its position in Ionis Pharmaceuticals Inc (NASDAQ:) by selling 18932 shares, totaling $693,100. This continues a sell-off pattern observed in the previous week, suggesting a strategic shift away from the pharmaceutical company.
A smaller transaction involved the sale of a modest 100 shares of Markforged Holding Corp (NYSE:MKFG), divided equally between the ARKQ and ARKX (NYSE:) ETFs, for a total value of $415. Although the amount is minor, it’s worth noting as it follows a similar sale from the previous Tuesday.
On the flip side, ARK has shown increasing interest in Beam Therapeutics Inc (NASDAQ:BEAM), buying a total of 36679 shares across its ARKK and ARKG ETFs, valued at $1,024,444. This purchase adds to the accumulation trend seen on the previous Friday, indicating ARK’s growing conviction in the company’s potential.
Investors following ARK’s trading patterns may find these transactions to be a signal of Cathie Wood’s strategic bets in the rapidly evolving biotech sector. As ARK continues to adjust its positions, market watchers will no doubt keep a close eye on these developments to gauge the ETFs’ future direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
